한글목차

세계의 체외진단용 시약 시장 규모는 2024년에 604억 5,000만 달러에 달할 것으로 보이며, 예측 기간 중 CAGR은 7.7%로 전망되고 있으며, 2029년에는 874억 1,000만 달러에 달할 것으로 예측됩니다.

체외진단(IVD) 기술의 채택이 증가함에 따라 IVD 시약에 대한 수요가 증가하고 있습니다. 따라서 새로운 진단 기술이 FDA 및 EMA와 같은 규제기관의 승인을 받으면 IVD 시약에 대한 수요가 증가할 것으로 예상됩니다.

IVD 시약 시장은 유형별로 항체, 항원, 정제 단백질, 펩티드, 올리고뉴클레오티드, 핵산 프로브, 기타 IVD 시약으로 분류됩니다. 진단 분야에서 PCR 기반 검사가 확산되면서 IVD 시약 시장에서 올리고뉴클레오티드에 대한 수요가 증가하고 있습니다. 올리고뉴클레오티드는 감염성 질환 및 유전자 검사에 광범위하게 적용되고 있습니다.

IVD 시약 시장은 용도별로 감염, 종양학, 내분비학, 심장학, 혈액검사, 유전자 검사, 자가면역질환, 알레르기 진단, 약물 모니터링 및 검사, 기타 용도로 구분됩니다. 감염성 질환 분야는 감염성 질환에 대한 연구개발 활동과 제품 승인 건수가 증가함에 따라 체외진단용 시약 시약 시장에서 가장 높은 점유율을 차지하고 있습니다.

세계 IVD 시약 시장은 북미, 유럽, 아시아태평양, 중동 및 아프리카, 라틴아메리카, GCC 국가 등 6개 지역으로 분류됩니다. 예측 기간 중 IVD 시약 시장은 아시아태평양에서 가장 빠르게 성장할 것으로 예상됩니다. 예측 기간 중 아시아태평양 시장은 의료 지출 증가와 광범위한 인구 기반 등의 요인으로 인해 가장 빠른 속도로 발전할 것으로 예상됩니다.

세계의 체외진단용 시약 시장에 대해 조사했으며, 유형별, 기술별, 용도별, 검사 유형별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
• 밸류체인 분석
• 공급망 분석
• 에코시스템 분석
• 투자와 자금조달 시나리오
• 기술 분석
• 특허 분석
• 무역 분석
• 2024-2025년의 주요 컨퍼런스와 이벤트
• Porter's Five Forces 분석
• 규제 분석
• 주요 이해관계자와 구입 기준
• AI/생성형 AI가 IVD 시약 시장에 미치는 영향

제6장 IVD 시약 시장(유형별)

• 서론
• 항체
• 항원, 정제 단백질, 펩티드
• 올리고뉴클레오티드
• 핵산 프로브
• 기타

제7장 IVD 시약 시장(기술별)

• 서론
• 면역 어세이
• 임상화학
• 분자진단
• 혈액학
• 미생물학
• 응고와 지혈
• 요검사
• 크로마토그래피와 질량분석
• 면역조직화학

제8장 IVD 시약 시장(용도별)

• 서론
• 감염증
• 종양학
• 내분비학
• 심장병
• 혈액검사
• 유전자 검사
• 자가면역질환
• 알레르기 진단
• 약물 모니터링과 검사
• 기타

제9장 IVD 시약 시장(검사 유형별)

• 서론
• 임상 검사
• POC(Point of Care) 테스트

제10장 IVD 시약 시장(최종사용자별)

• 서론
• 병원과 클리닉
• 임상 검사실
• 혈액은행
• 홈케어
• 제약회사·바이오테크놀러지 기업
• 학술기관
• 기타

제11장 IVD 시약 시장(지역별)

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 면역학, 출생전 검사, 암검사에 대한 주목이 증가 시장을 촉진
  • 중동 및 아프리카의 거시경제 전망
• GCC 국가
  • GCC 국가의 거시경제 전망
  • 사우디아라비아 왕국
  • 아랍에미리트
  • 기타

제12장 경쟁 구도

• 개요
• 주요 참여 기업의 전략/강점, 2023년
• 매출 분석, 2021-2023년
• 시장 점유율 분석, 2023년
• 기업 가치 평가와 재무 지표
• 브랜드/제품 비교
• 기업 평가 매트릭스 : 주요 참여 기업, 2023년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
• 경쟁 시나리오

제13장 기업 개요

• 주요 참여 기업
  • DANAHER CORPORATION
  • F. HOFFMANN-LA ROCHE LTD.
  • ABBOTT
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC INC.
  • ILLUMINA, INC.
  • BIOMERIEUX
  • BD
  • HOLOGIC, INC.
  • BIO-RAD LABORATORIES, INC.
  • SYSMEX CORPORATION
  • QIAGEN N.V.
  • AGILENT TECHNOLOGIES, INC.
  • REVVITY
  • DIASORIN S.P.A.
  • GRIFOLS, S.A.
  • WERFEN, S.A.
  • QUIDELORTHO CORPORATION
  • CHEMBIO DIAGNOSTICS, INC.
  • SURMODICS, INC.
  • MERCK KGAA
• 기타 기업
  • MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
  • CANVAX
  • PRESTIGE DIAGNOSTICS
  • ADALTIS S.R.L.
  • RANDOX LABORATORIES LTD.

제14장 부록

영문목차

The global IVD reagents market is valued at an estimated 87.41 billion in 2029 and is projected to reach USD 60.45 billion by 2024, at a CAGR of 7.7% during the forecast period. The increasing adoption of IVD technologies has led to a growing need of IVD reagents. The demand for IVD reagents is therefore expected to increase as new diagnostic technologies are getting FDA, EMA approvals from regulatory bodies.

"The oligonucleotide segment is projected to witness the highest growth rate in the IVD reagents market, by type, during the forecast period."

Based on type, the IVD reagents market is segmented into antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. The growing adoption of PCR-based tests in diagnostics has boosted the demand for oligonucleotide in the IVD reagents market. Oligonucleotides have wide range of applications in infectious diseases and genetic testing.

"The infectious disease segment to witness the highest share in the IVD reagents market, in 2023, by application"

Based on application, the IVD reagents market is segmented into infectious diseases, oncological applications, endocrinological applications, cardiological applications, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing and other applications. The infectious diseases segment experience highest market share of IVD reagents market due to rising number of R&D activities and product approvals for infectious disease applications.

"The Asia Pacific region is projected to witness highest growth rate in the IVD reagents market during the forecast period"

The global IVD reagents market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Over the span of the forecast period, the IVD reagents market is expected to grow at the fastest rate in the Asia Pacific region. Over the projected period, the Asia Pacific market is expected to develop at the greatest rate due to factors such increasing healthcare spending and an extensive population base.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 42%, Tier 2 - 30%, and Tier 3 - 28%
• By Designation: C-level - 46%, Director-level - 23%, and Others - 31%
• By Region: North America - 23%, Europe - 44%, Asia Pacific - 28%, Latin America - 3%, Middle East & Africa - 1%, and the GCC Countries - 1%

Lists of Companies Profiled in the Report:

Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), BioMerieux (France), BD (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), DiaSorin S.p.A (Italy), Grifols, S.A. (Spain), Werfen, S.A. (Spain), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Merck KGaA (Germany), MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Tokyo), Canvax (Spain), Prestige Diagnostics (US), Adaltis S.r.l. (Italy), and Randox Laboratories Ltd. (UK)

Study Coverage:

In this report, the IVD reagents market has been categorized based on type (antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents), technology (immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, chromatography & mass spectrometry, immunohistochemistry), application (infectious diseases, oncological applications, endocrinological application, cardiology application, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, and other applications), test type (laboratory test, and point-of-care tests), end user (hospitals & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries).

Information regarding the main drivers, restraints, opportunities, and challenges influencing the IVD reagents market's expansion is includes detail in this study. An intensive study of the key players in the IVD reagents market has been done to provide insights into their business profile, service offered, note worthy strategies, acquisitions and expansions, and other deals made pertaining to the market. This study examines the fragmented landscape of emerging IVD reagents startups.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD reagents marketand the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restaints.

The report provides insights on the following pointers:

• Analysis of key drivers: (growing geriatric population, gradual shift towards point-of-care testing and automated analyzers, rise in early diagnosis and personalized medicine, increasing adoption of third-party quality controls, growing biotechnology and biopharmaceutical industries, increasing funding for R&D activities), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (increasing development of biomarkers, rising significance of companion diagnostics, market growth opportunities in emerging economies, and growing trend of digitalization), and challenges (operational challenges in clinical process) influencing the growth of the in IVD reagents market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the IVD reagents market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, and investments in the IVD reagents market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like include F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific Inc. (US) are among others, in the IVD reagents market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 MARKET RECONCILIATION

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Approach 3: Primary interviews
    • 2.2.1.4 Growth forecast
    • 2.2.1.5 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
  • 2.4.1 STUDY-RELATED ASSUMPTIONS
  • 2.4.2 PARAMETRIC ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IVD REAGENTS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY
• 4.3 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE AND COUNTRY
• 4.4 IVD REAGENTS MARKET, BY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing geriatric population
    • 5.2.1.2 Gradual shift toward point-of-care testing and automated analyzers
    • 5.2.1.3 Rise in early diagnosis and personalized medicine
    • 5.2.1.4 Increasing adoption of third-party quality controls
    • 5.2.1.5 Growing biotechnology and biopharmaceutical industries
    • 5.2.1.6 Increasing funding for R&D activities
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.2.2 Stringent regulatory requirements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing development of biomarkers
    • 5.2.3.2 Rising significance of companion diagnostics
    • 5.2.3.3 Market growth opportunities in emerging economies
    • 5.2.3.4 Growing trend of digitalization
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Operational challenges in clinical process
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
  • 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
  • 5.9.2 ADJACENT TECHNOLOGIES
    • 5.9.2.1 Multiplexed point-of-care testing
    • 5.9.2.2 Nucleic acid lateral flow immunoassay
    • 5.9.2.3 DNA-based detection
    • 5.9.2.4 Immunodiagnostics
    • 5.9.2.5 Dual path technology
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA
  • 5.11.2 EXPORT DATA
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF SUPPLIERS
  • 5.13.4 BARGAINING POWER OF BUYERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 REGULATORY ANALYSIS
  • 5.14.1 REGULATORY LANDSCAPE
    • 5.14.1.1 North America
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
    • 5.14.1.3 Asia Pacific
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 India
    • 5.14.1.4 Latin America
      • 5.14.1.4.1 Brazil
    • 5.14.1.5 Middle East
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.14.2.1 North America
    • 5.14.2.2 Europe
    • 5.14.2.3 Asia Pacific
    • 5.14.2.4 Latin America
    • 5.14.2.5 Middle East & Africa
    • 5.14.2.6 GCC Countries
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA
• 5.16 IMPACT OF AI/GENERATIVE AI ON IVD REAGENTS MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL FOR IVD REAGENTS
  • 5.16.3 AI USE CASES
  • 5.16.4 KEY COMPANIES IMPLEMENTING AI
  • 5.16.5 FUTURE OF GENERATIVE AI ON IVD REAGENTS

6 IVD REAGENTS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 ANTIBODIES
  • 6.2.1 MONOCLONAL ANTIBODIES
    • 6.2.1.1 Increasing incidence of cancer to stimulate growth
  • 6.2.2 POLYCLONAL ANTIBODIES
    • 6.2.2.1 Rising prevalence of infectious diseases and autoimmune disorders to support growth
• 6.3 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
  • 6.3.1 INCREASING FOCUS ON ADVANCED PRECISION MEDICINE TO ENCOURAGE GROWTH
• 6.4 OLIGONUCLEOTIDES
  • 6.4.1 GROWING INCLINATION TOWARD MOLECULAR DIAGNOSTICS TO DRIVE MARKET
• 6.5 NUCLEIC ACID PROBES
  • 6.5.1 NEED FOR EARLY DISEASE DETECTION AND MONITORING LOW-ABUNDANCE BIOMARKERS TO AID GROWTH
• 6.6 OTHER IVD REAGENTS

7 IVD REAGENTS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 IMMUNOASSAYS
  • 7.2.1 RISING TREND OF AUTOMATION TO PROMOTE GROWTH
• 7.3 CLINICAL CHEMISTRY
  • 7.3.1 RISING PREVALENCE OF DIABETES TO BOOST SEGMENT
• 7.4 MOLECULAR DIAGNOSTICS
  • 7.4.1 GROWING DEMAND FOR BLOOD SCREENING AND POINT-OF-CARE TESTING TO FUEL MARKET
• 7.5 HEMATOLOGY
  • 7.5.1 INCREASING FOCUS ON STEM CELL RESEARCH TO SPEED UP GROWTH
• 7.6 MICROBIOLOGY
  • 7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
• 7.7 COAGULATION & HEMOSTASIS
  • 7.7.1 GROWING USE OF ANTICOAGULATION THERAPY TO PROPEL MARKET
• 7.8 URINALYSIS
  • 7.8.1 RISING PREVALENCE OF KIDNEY DISEASES TO SUPPORT MARKET GROWTH
• 7.9 CHROMATOGRAPHY & MASS SPECTROMETRY
  • 7.9.1 INCREASING APPLICATIONS IN DISEASE SCREENING, FORENSIC ANALYSIS, AND DRUG THERAPY TO BOOST MARKET
• 7.10 IMMUNOHISTOCHEMISTRY
  • 7.10.1 GROWING NUMBER OF LABORATORY TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET

8 IVD REAGENTS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 INFECTIOUS DISEASES
  • 8.2.1 INCREASING PRODUCT LAUNCHES AND APPROVALS TO BOOST MARKET
• 8.3 ONCOLOGICAL APPLICATIONS
  • 8.3.1 GROWING EMPHASIS ON EARLY DIAGNOSIS AND QUALITY TREATMENT TO FUEL MARKET
• 8.4 ENDOCRINOLOGICAL APPLICATIONS
  • 8.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO SUSTAIN GROWTH
• 8.5 CARDIOLOGICAL APPLICATIONS
  • 8.5.1 CHANGING LIFESTYLES IN DEVELOPED AND DEVELOPING COUNTRIES TO PROPEL MARKET
• 8.6 BLOOD SCREENING
  • 8.6.1 RISING ADOPTION OF AUTOMATED DIAGNOSTIC INSTRUMENTS TO FACILITATE GROWTH
• 8.7 GENETIC TESTING
  • 8.7.1 INCREASING ADOPTION OF GENETIC TESTING TO DIAGNOSE RARE AND FATAL DISEASES TO SUSTAIN GROWTH
• 8.8 AUTOIMMUNE DISEASES
  • 8.8.1 GROWING ADVANCEMENTS IN LABORATORY TECHNOLOGY, REAGENTS, AND ALTERNATIVE ASSAY METHODOLOGIES TO DRIVE MARKET
• 8.9 ALLERGY DIAGNOSTICS
  • 8.9.1 GROWING FOCUS ON ALLERGY THERAPY AND PREVENTION TO ACCELERATE GROWTH
• 8.10 DRUG MONITORING & TESTING
  • 8.10.1 GROWING IMPLEMENTATION OF DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
• 8.11 OTHER APPLICATIONS

9 IVD REAGENTS MARKET, BY TEST TYPE

• 9.1 INTRODUCTION
• 9.2 LABORATORY TESTS
  • 9.2.1 INCREASING NEED FOR AUTOMATION TO EXPEDITE GROWTH
• 9.3 POINT-OF-CARE TESTS
  • 9.3.1 NEED TO CLOSELY MONITOR PATIENT CONDITIONS TO AUGMENT GROWTH

10 IVD REAGENTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 INCREASING SPECIALTY DIAGNOSTIC TESTS TO ACCELERATE GROWTH
• 10.3 CLINICAL LABORATORIES
  • 10.3.1 LARGE REFERENCE LABORATORIES
    • 10.3.1.1 Need for specialized testing capabilities and minimal turnaround time to boost market
  • 10.3.2 SMALL & MEDIUM-SIZED LABORATORIES
    • 10.3.2.1 Growing adoption of automated and semi-automated instruments to support growth
• 10.4 BLOOD BANKS
  • 10.4.1 GROWING NUMBER OF TRAUMA CASES AND AVAILABILITY OF SOPHISTICATED SURGICAL PROCEDURES TO FUEL MARKET
• 10.5 HOME CARE SETTINGS
  • 10.5.1 GROWING PREFERENCE FOR AT-HOME TESTING KITS TO DRIVE MARKET
• 10.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.6.1 INCREASING RESEARCH & DEVELOPMENT EFFORTS TO CONTRIBUTE TO GROWTH
• 10.7 ACADEMIC INSTITUTES
  • 10.7.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO FAVOR GROWTH
• 10.8 OTHER END USERS

11 IVD REAGENTS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Established reimbursement framework to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Rising incidence of chronic and infectious lifestyle diseases to propel market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Increasing investments in clinical diagnostics research to drive market
  • 11.3.3 UK
    • 11.3.3.1 Rising adoption of genome-based testing to promote growth
  • 11.3.4 FRANCE
    • 11.3.4.1 High healthcare expenditure and rising investments in genomic medicine to boost market
  • 11.3.5 ITALY
    • 11.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising adoption of immunoassay reagents to drive market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Rise in social health insurance programs to encourage growth
  • 11.4.3 CHINA
    • 11.4.3.1 Growing focus on preventive care to boost demand
  • 11.4.4 INDIA
    • 11.4.4.1 Rising prevalence of chronic diseases to fuel market
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Rising prevalence of diabetes to stimulate growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing establishment of clinical laboratories to boost market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GROWING FOCUS ON IMMUNOLOGY AND PRENATAL & CANCER TESTING TO DRIVE MARKET
  • 11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
  • 11.7.2 KINGDOM OF SAUDI ARABIA
    • 11.7.2.1 Rising healthcare expenditure to promote growth
  • 11.7.3 UNITED ARAB EMIRATES
    • 11.7.3.1 Increasing development of advanced healthcare infrastructure to expedite growth
  • 11.7.4 OTHER GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021-2023
• 12.3 REVENUE ANALYSIS, 2021-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Technology footprint
    • 12.7.5.3 Application footprint
    • 12.7.5.4 Test type footprint
    • 12.7.5.5 Region footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 12.8.5.1 Detailed list of key startups/SMEs
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Deals
      • 13.1.1.3.2 Expansions
      • 13.1.1.3.3 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 ABBOTT
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 SIEMENS HEALTHINEERS AG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 THERMO FISHER SCIENTIFIC INC.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
      • 13.1.5.3.2 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 ILLUMINA, INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Deals
  • 13.1.7 BIOMERIEUX
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 BD
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Deals
  • 13.1.9 HOLOGIC, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches and approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 BIO-RAD LABORATORIES, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Deals
  • 13.1.11 SYSMEX CORPORATION
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches and approvals
      • 13.1.11.3.2 Deals
      • 13.1.11.3.3 Expansions
  • 13.1.12 QIAGEN N.V.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 AGILENT TECHNOLOGIES, INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
      • 13.1.13.3.2 Expansions
  • 13.1.14 REVVITY
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
      • 13.1.14.3.2 Other developments
  • 13.1.15 DIASORIN S.P.A.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Deals
  • 13.1.16 GRIFOLS, S.A.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
  • 13.1.17 WERFEN, S.A.
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Deals
  • 13.1.18 QUIDELORTHO CORPORATION
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Deals
      • 13.1.18.3.2 Expansions
  • 13.1.19 CHEMBIO DIAGNOSTICS, INC.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products offered
  • 13.1.20 SURMODICS, INC.
    • 13.1.20.1 Business overview
    • 13.1.20.2 Products offered
  • 13.1.21 MERCK KGAA
    • 13.1.21.1 Business overview
    • 13.1.21.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
  • 13.2.2 CANVAX
  • 13.2.3 PRESTIGE DIAGNOSTICS
  • 13.2.4 ADALTIS S.R.L.
  • 13.2.5 RANDOX LABORATORIES LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS